| Chemical Properties | Back Directory | [Boiling point ]
612.2±55.0 °C(Predicted) | [density ]
1.347±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (175.55 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.46±0.70(Predicted) | [color ]
Light yellow to green yellow |
| Hazard Information | Back Directory | [Uses]
NXP800 (CCT361814) is a potent and orally active heat shock factor 1 (HSF1) pathway inhibitor. NXP800 has?the?potential?for?cancer research[1][2]. | [Biological Activity]
NXP800 (CCT361814) is a potent heat shock factor 1 (HSF1) inhibitor. NXP800 has the potential for cancer research[1].
NXP800 (example 169) inhibits U20S cells viability (IC50=0.056 μM)[1]. | [in vivo]
NXP800 (35 mg/kg; po; once daily for 20 days) inhibits the established SK-OV-3 human ovarian cancer solid tumor xenografts grown subcutaneously, with tumor growth inhibition (TGI) of 120% relative to control[2].
Pharmacokinetic Analysis[2]
| Species | Route | Dose (mg/kg) | Tmax (h) | AUClast (ng·h/mL) | Cltb (mL/min/kg) | t1/2 (h) | F (%) | AUCu0-t (h·nM) | Free Cav0-24h (nM) | Clu (mL/min/kg) | | mouse | po/iv | 5/5 | 2.0 | 6000 (7800-4600) (po) | 10 (10-9.7) (iv) | 4.0 | 42 (po) | 72 | 3.3 | 830 (iv) | | rat | po/iv | 5/1 | 6.0 | 2600 (po) | 24 (iv) | 3.1 | 45 (po) | 86 | 3.7 | 730 (iv) | | dog | po/iv | 2.5/0.5 | 2.0 | 250 (po) | 21 (iv) | 1.4 | 9.1 (po) | 35 | 1.9 | 150 (iv) |
| [IC 50]
HSF1 | [References]
[1]. Keith Jones, et al. Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1. WO2015049535A1. |
|
|